Hiroshi Fukuhara
Overview
Explore the profile of Hiroshi Fukuhara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
2056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, et al.
Int J Urol
. 2024 Nov;
PMID: 39575880
Background: While the occurrence of immune-related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, the prognostic significance of treatment-related adverse events (trAEs) in...
2.
Oshina T, Yamada Y, Fujimura T, Taguchi S, Akiyama Y, Kamei J, et al.
Curr Oncol
. 2024 Aug;
31(8):4762-4768.
PMID: 39195339
Background: Salvage robot-assisted radical prostatectomy (sRARP) after PSA failure in patients who underwent initial radiotherapy or focal therapy has rarely been reported in Japan. We aimed to report the oncologic...
3.
Sugawara K, Taguchi S, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, et al.
JPEN J Parenter Enteral Nutr
. 2024 Jul;
48(6):746-755.
PMID: 38953890
Background: This study aimed to evaluate if combining low muscle mass with additional body composition abnormalities, such as myosteatosis or adiposity, could improve survival prediction accuracy in a large cohort...
4.
Kato T, Matsumoto R, Yokomizo A, Tohi Y, Fukuhara H, Fujii Y, et al.
BJU Int
. 2024 Jun;
134(4):652-658.
PMID: 38886979
Objective: To report the outcomes of repeat biopsies, metastasis and survival in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study, a prospective observational study for Japanese patients, initiated in...
5.
Nagase M, Ando H, Beppu Y, Kurihara H, Oki S, Kubo F, et al.
J Am Soc Nephrol
. 2024 Jun;
35(10):1366-1380.
PMID: 38844335
No abstract available.
6.
Higashihara E, Harada T, Fukuhara H
Expert Opin Pharmacother
. 2024 May;
25(7):819-832.
PMID: 38773961
Introduction: Juxtaglomerular apparatus (JGA)-mediated homeostatic mechanism links to how sodium-glucose cotransporter 2 inhibitors (SGLT2is) slow progression of chronic kidney disease (CKD) and may link to how tolvaptan slows renal function...
7.
Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, et al.
Sci Rep
. 2024 Mar;
14(1):7607.
PMID: 38556562
A total of 739 patients underwent RARP as initial treatment for PCa from November 2011 to October 2018. Data on BCR status, clinical and pathological parameters were collected from the...
8.
Takeuchi T, Hattori-Kato M, Okuno Y, Nomiya A, Fukuhara H, Zaitsu M, et al.
Cureus
. 2024 Feb;
16(1):e52926.
PMID: 38406143
Background In addition to genetic predisposition, occupational and environmental factors are important for the risk of prostate cancer. We investigated the effect of single nucleotide polymorphisms (SNPs) on the development...
9.
Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, et al.
Strahlenther Onkol
. 2024 Jan;
200(8):676-683.
PMID: 38180494
Background: Although robot-assisted radical prostatectomy (RARP) and intensity-modulated radiotherapy are the leading respective techniques of prostatectomy and radiotherapy for localized prostate cancer, almost no study has directly compared their outcomes;...
10.
Taguchi S, Sugawara K, Gonoi W, Hanaoka S, Shiomi S, Kishitani K, et al.
Clin Nutr
. 2023 Dec;
43(1):134-141.
PMID: 38041939
Background & Aims: While skeletal muscle index (SMI) is the most widely used indicator of low muscle mass (or sarcopenia) in oncology, optimal cut-offs (or definitions) to better predict survival...